These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32683135)

  • 1. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance.
    Soran H; France M; Adam S; Iqbal Z; Ho JH; Durrington PN
    Atherosclerosis; 2020 Aug; 306():33-40. PubMed ID: 32683135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
    Kim BK; Hong SJ; Lee YJ; Hong SJ; Yun KH; Hong BK; Heo JH; Rha SW; Cho YH; Lee SJ; Ahn CM; Kim JS; Ko YG; Choi D; Jang Y; Hong MK;
    Lancet; 2022 Jul; 400(10349):380-390. PubMed ID: 35863366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
    Soran H; Adam S; Durrington PN
    Atherosclerosis; 2018 Nov; 278():135-142. PubMed ID: 30273874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding ezetimibe to statin therapy: latest evidence and clinical implications.
    Vavlukis M; Vavlukis A
    Drugs Context; 2018; 7():212534. PubMed ID: 30023003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention.
    Soran H; Adam S; Iqbal Z; Durrington P
    BMJ Open; 2022 May; 12(5):e050266. PubMed ID: 35613766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
    Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
    Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for more intensive cholesterol lowering.
    Soran H; Kwok S; Adam S; Ho JH; Durrington PN
    Curr Opin Lipidol; 2017 Aug; 28(4):291-299. PubMed ID: 28509674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study.
    Fras Z; Mikhailidis DP
    Curr Med Res Opin; 2008 Sep; 24(9):2467-76. PubMed ID: 18655751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
    Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
    Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk.
    Mazza A; Nicoletti M; Lenti S; Torin G; Rigatelli G; Pellizzato M; Fratter A
    J Med Food; 2021 Jan; 24(1):59-66. PubMed ID: 32456525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.
    Ara R; Tumur I; Pandor A; Duenas A; Williams R; Wilkinson A; Paisley S; Chilcott J
    Health Technol Assess; 2008 May; 12(21):iii, xi-xiii, 1-212. PubMed ID: 18485273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of the patient with statin intolerance.
    Vandenberg BF; Robinson J
    Curr Atheroscler Rep; 2010 Jan; 12(1):48-57. PubMed ID: 20425271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
    N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
    Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
    Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model.
    Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Rees A; Wilkinson A; Durrington P; Chilcott J
    Am J Cardiovasc Drugs; 2008; 8(6):419-27. PubMed ID: 19159125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
    Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA
    Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.